Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
451. |
ECCT/16/11/04 | RV456 A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo |
Principal Investigator(s) 1. JANET OYIEKO Site(s) in Kenya KOMBEWA CLINICAL RESEARCH CENTRE |
28-01-2017 |
View |
452. |
ECCT/16/12/02 | Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial. |
Principal Investigator(s) 1. ISAAC TSIKHUTSU Site(s) in Kenya KEMRI/WRP, KERICHO |
10-01-2017 |
View |
453. |
ECCT/16/08/01 | A5349/TBTC S31 A5349/TBTC S31 “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial” |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
13-12-2016 |
View |
454. |
ECCT/16/09/03 | Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya. Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya. |
Principal Investigator(s) 1. Dr.Pauline NM Mwinzi Site(s) in Kenya KEMRI CGHR |
28-11-2016 |
View |
455. |
ECCT/16/08/03 | IMPAACT 2001 A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed project |
27-10-2016 |
View |
456. |
ECCT/16/07/06 | Cups or Cash for Girls Trial Menstrual cups and cash transfer to reduce sexual and reproductive harm and school dropout in adolescent schoolgirls in western Kenya: a cluster randomised controlled trial |
Principal Investigator(s) 1. Penelope Anne Phillips-Howard 2. Daniel Oluoch Kwaro Site(s) in Kenya Siaya County |
19-10-2016 |
View |
457. |
ECCT/16/09/02 | Monitoring Pre-Exposure Prophylaxis for Young Adult Women ( (MPYA) Next generation real-time monitoring for PrEP adherence in young adult women. |
Principal Investigator(s) 1. Prof. Elizabeth Anne Bukusi Bukusi 2. Dr. Stella Njuguna Njuguna Site(s) in Kenya 1. KISUMU SITE (Kisumu county) |
27-09-2016 |
View |
458. |
ECCT/16/07/05 | HESTIA 1 Multicentre, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell disease |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Kemri CRDR research center at Chandaria Health Centre Dagoretti (Nairobi City county) 3. Clinical Research Annex at the Siaya County Referral Hospital (Siaya county) 4. Kondele Children’s Hospital, KEMRI – Centre for Clinical Research (Kisumu county) |
19-09-2016 |
View |
459. |
ECCT/16/05/02 | Monitoring Pre-exposure Prophylaxis for Young Adult women (MPYA) Next generation real-time monitoring for PrEP adherence in young Kenyan women |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. Thika Partners Study Clinic (Partners in Health Research and Development) (Kiambu county) 2. Partners in Prevention, Kisumu Site (Kisumu county) |
07-09-2016 |
View |
460. |
ECCT/16/07/02 | A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events |
Principal Investigator(s) 1. Mark Loeb Site(s) in Kenya The Aga Khan University Hospital |
17-08-2016 |
View |